Revised and up to date, the Second Edition includes valuable information that addresses questions such as:
* What is transparency and why do we care?
* How can financial statements inform investors?
* How can financial statements mislead investors?
* How has the Sarbanes-Oxley Act changed companies' financial disclosures?
* What should you look for in financial disclosures when judging a company's financial health?
* How do financial statements relate to the value of a company's stock?
* Why is cash flow so important to a company's financial health?
Throughout Analysis of Financial Statements, Second Edition, the authors demonstrate the nuts and bolts of financial analysis by applying the techniques to actual companies. The authors set the stage for financial analysis in Part One with their discussions of financial statements and the quality of financial statements. In Part Two, they walk you through how to judge a company's financial health using financial disclosures in financial ratio analysis, earnings analysis, and cash flow analysis. In Part Three, the authors take analysis a step further by discussing how investors and creditors can use financial statements to more effectively assess a company's performance and risk. Peterson and Fabozzi wrap up this Second Edition with a set of lessons for investors and analysts:
Lesson 1: Understand what you are looking at
Lesson 2: Read the fine print
Lesson 3: If it's too good to be true, it may be
Lesson 4: Follow the money
Lesson 5: Understand the risks
|Series:||Frank J. Fabozzi Series , #141|
|Sold by:||Barnes & Noble|
|File size:||8 MB|
About the Author
Frank J. Fabozzi (New Hope, PA) is the Frederick Frank Adjunct Professor of Finance in the School of Management at Yale University. Frank is a Fellow of the International Center for Finance at Yale University, the editor of the Journal of Portfolio Management, a member of Princeton University’s Advisory Council for the Department of Operations Research and Financial Engineering, and a trustee of the BlackRock complex of closed-end funds and Guardian Life sponsored open-end mutual funds.